AHAnnie Harroche

Annie Harroche

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Annie Harroche has a total of 128 co-authors. Here are the top co-authors by number of shared publications:

  • Hervé Chambost

    AP‐HM, Department of Paediatric Haematology Oncology Institut National De La Santé Et De La Recherche médicale, Institut national De La Recherche Agronomique Centre Recherche En CardioVasculaire et Nutrition Children Hospital La Timone & Aix Marseille University Marseille France

    5 shared publications
  • Roseline D Oiron

    Centre de Référence de l'Hémophilie et des Maladies Hémorragiques Rares, Hôpital Bicêtre APHP, and HITh, UMR_S1176, INSERM Université Paris‐Saclay, Le Kremlin‐Bicêtre Paris France

    5 shared publications
  • Sandrine Meunier

    Reference Center of Hemophilia and Other Rare Bleeding Disorders, Hospices Civils de Lyon, 69002 Lyon, France

    4 shared publications
  • Yoann Huguenin

    Haemophilia Treatment Centre, University Hospital of Bordeaux, Bordeaux, France

    4 shared publications
  • Any Beltran Anzola

    CEReSS / UR 3279, Center for Studies and Research on Health Services and Quality of Life, Aix Marseille University, Marseille, France

    3 shared publications
  • Clémence Tabélé

    CEReSS / UR 3279, Center for Studies and Research on Health Services and Quality of Life, Aix Marseille University, Marseille, France

    3 shared publications

Latest Publications

  • Open Access

    Management of von Willebrand Disease With a Factor VIII‐Poor von Willebrand Factor Concentrate: Results From the Paediatric Cohort of a Prospective Observational Post‐Marketing Study

    by Jenny Goudemand, Annie Borel‐Derlon, Ségolène Claeyssens, Hervé Chambost, Guillaume Mourey, Annie Harroche, Sandrine Meunier, Céline Henriet, Thierry Leroi, Sophie Susen, et al.

    Introduction: Although clinical experience of a triple‐secured, plasma‐derived, von Willebrand factor (pdVWF), almost devoid of Factor VIII (FVIII) in adults with von Willebrand disease (VWD), is widely reported, its use in children is less documented. Aim: To explore the safety and efficacy of this concentrate in real‐life, in children <12 years old. Methods: Data from 30 paediatric patients enrolled in a prospective, 3‐year observational, post‐marketing study in France were analysed. Efficacy and safety were assessed in two cohorts: 0–6 and 6–11 years old. Results: The population included 14 children <6 years of age and 16 children aged 6–11 years. Most patients (80%) were severely affected (von Willebrand factor ristocetin cofactor activity [VWF:RCo] ≤ 15 IU/dL), including 30% with Type 3 VWD. Children received pdVWF for 16 major bleeds, 138 minor bleeds, 7 major surgeries, 8 minor surgeries and 12 invasive procedures. Efficacy was rated excellent or good in 100% of major bleeds or surgeries. The dose per infusion was approximately 50 IU/kg. By age group, median doses per infusion varied from 49 to 73 IU/kg for patients <6 years and from 46 to 59 IU/kg for patients 6–11 years, according to clinical situation. FVIII coadministration/correction was more frequent in Type 3 VWD, regardless of patient's age. Of five children receiving long‐term prophylaxis, breakthrough bleeding occurred in 1.6% of infusions and median annualised bleeding rate was 0.8. No safety concerns were raised. Conclusion: This analysis enlarges clinical experience of an FVIII‐poor pdVWF in the paediatric population. This concentrate offers safe and effective treatment regardless of VWD severity.

  • Open Access

    Navigating the Transition From Adolescence to Adulthood Among Young People With Severe Haemophilia: The Qualitative Phase of the TRANSHEMO Project

    by Marie-Anaïs Roques, Natacha Rosso-Delsemme, Amandine Celli, Ngoc Anh Thu Nguyen, Martin Postzich, Sabine Castet, Yoann Huguenin, Annie Harroche, Anne Lienhart, Sandrine Meunier, et al.

    Introduction: Haemophilia causes spontaneous or prolonged bleeding due to a deficiency in clotting factor VIII (haemophilia A) or IX (haemophilia B). Although substitutive therapies and regular follow‐up can prevent severe haemorrhagic events, adherence to treatment remains a challenge. Transitioning from adolescence to adulthood and from paediatric to adult care is particularly complex for young people with severe haemophilia (PwSH), as it involves gaining autonomy in health management. Objectives: This study aimed to explore factors influencing the success of the transition process in young PwSH, with a focus on adherence to healthcare. Methods: This qualitative study was part of the mixed‐methods TRANSHEMO project. Participants were selected from the quantitative phase of the TRANSHEMO project based on two criteria: adolescents/young adults and adherent/nonadherent to healthcare. Interviews were conducted via video conferencing, transcribed, and thematically analysed to identify key themes affecting the transition process. Results: Twenty‐two interviews were conducted. Four major themes emerged as critical to transition success: (1) Care factors [continuity of care, treatment rituals, and evolving therapies]; (2) Family and social factors [support from family, friends, peers, and overprotection]; (3) Personal factors [understanding haemophilia, risk management, optimism, and coping strategies]; and (4) Autonomy [secondary benefits, independence, proactivity in disease management, and accompaniment by caregivers]. Conclusion: Based on the enlightened determinants, supportive strategies and patient education programs should focus on the development of autonomy, personal factors such as acquisition and application of health literacy in haemophilia care, and family factors such as support from family.


  • Open Access

    Contrasting Approaches in the Implementation of GRADE Methodology in Guidelines for Haemophilia and Von Willebrand Disease

    by Mark W. Skinner, Manuela Albisetti, Jesús Ardila, Jan Astermark, Jan Blatny, Manuel Carcao, Pratima Chowdary, Nathan T. Connell, Miguel Crato, Yesim Dargaud, et al.

    Introduction: The 2024 ISTH clinical practice guideline (CPG) for treatment of congenital haemophilia, the NBDF‐McMaster Guideline on Care Models for Haemophilia Management, and ASH ISTH NBDF WFH guidelines on the diagnosis and management of VWD all utilised GRADE methodology.Aim: Discuss missed opportunities and the methodological approach of the ISTH Guideline in contrast to how GRADE was previously applied in rare diseases.Methods: Critically analyse the methodology of each guideline along with best practices in the use of GRADE. Where applicable, the WFH Guidelines for the Management of Haemophilia were analysed.Results: Important differentiating features in applying GRADE were identified. Where a strong evidence base is lacking, data other than those from randomized controlled trials, which may not always be justified, need to be considered, including incorporation of outcomes important to people living with the disease. Justification and stakeholder input to prioritize questions requiring a new guideline, panel composition with necessary patient participation and content expertise were also found to be significant differentiating features.Conclusion: The puristic approach taken in the ISTH Guideline development process, without consideration of accepted adaptations to GRADE implementation, created a missed opportunity for progressing haemophilia care, leading to guideline recommendations that have been widely deemed invalid and obsolete by expert healthcare professionals and by those living with the condition, the very people who are expected to implement or bear the impact of the recommendations. Lessons learnt from this comparative analysis should guide future guideline development and encourage collaboration to further advance haemophilia.


  • International Society on Thrombosis and Haemostasis Clinical Practice Guideline for Treatment of Congenital Haemophilia—A Critical Appraisal

    by Manuela Albisetti, Jesús Ardila, Jan Astermark, Jan Blatny, Manuel Carcao, Pratima Chowdary, Nathan T. Connell, Miguel Crato, Yesim Dargaud, Roseline D'OIron, et al.

    Introduction: Evidence‐based clinical practice guidelines drive optimal patient care and facilitate access to high‐quality treatment. Creating guidelines for rare diseases such as haemophilia, where evidence does not often come from randomized controlled trials but from non‐randomized and well‐designed observational studies and real‐world data, is challenging. The methodology used for assessing available evidence should consider this critical fact. In formulating guidelines, it is essential to include treatment goals and patient preference.Aim: This paper comprehensively critiques, against this background, the recommendations of the ISTH clinical practice guidelines for the treatment of haemophilia.Methods: Each recommendation was critically reviewed against available evidence as well as existing guidelines and commented upon for its scientific validity, impact on clinical practice and access to care globally. The validity of the way in which the GRADE methodology was applied to existing evidence was also assessed.Results: The critique provided shows that these recommendations have major limitations: they did not state treatment goals and contradict existing guidelines; opportunities for providing access to innovation were missed when the therapeutic benefits of the products approved in the last decades were not included. A major reason for this is the inappropriate adoption of the GRADE methodology without adaptations and without considering treatment goals and patient‐relevant outcomes.Conclusion: These recommendations may mislead healthcare professionals, payers and governments and therefore cannot serve the patient community well. They setback the advances made in haemophilia care because they overlook important available evidence and do not guide clinical practice to contemporary standards.


  • Open Access

    Severe haemorrhages leading to a diagnosis of rare bleeding disorder occur at a very young age: A study from the FranceCoag network

    by Sandrine Meunier, Annie Harroche, Antoine Rauch, Cécile Bally, Yoann Huguenin, Romain Voltzenlogel, Clémence Tabélé, Hervé Chambost, Martine Balençon, France Coag

    Introduction: In the context of severe unexplained haemorrhage (SH), it is usual to seek haematological evaluation and investigate for an inherited rare bleeding disorder (IRBD). In such circumstances, appropriate screen can discriminate between IRBD and suspected child abuse. Yet, little information is available about the frequency of SH in the population of patients with IRBD.Aim: To collect epidemiologic data about SH and IRBD.Method: The database of the FranceCoag network has collected information about IRBD since January 2004. Based on data gathered up to 16 March 2022, a retrospective search was conducted for of SH events having occurred before or at the time of IRBD diagnosis. Demographics and diagnosis circumstances were retrieved, as well as information about SH, defined as any life‐threatening bleeding or intracranial haemorrhage.Results: Among the 13,433 patients of the database, 109 (0.8%) fulfilled inclusion criteria including a known date of IRBD diagnosis, haemophilia A or B (HA/HB) being the most frequent (82.5%). IRBD was discovered as a consequence of an SH event in 82.6% of the cases while CNS was involved in 55%. Severe and moderate HA/HB and other severe IRBD presented significantly more intracranial haemorrhage (p < .02) and a lower age at diagnosis (p = .03).Conclusions: These data support that any unusual SH should raise a suspicion of IRBD. Particularly before 1‐year of age, it is suggested to first confirm moderate or severe haemophilia and severe IRBD by standard coagulation tests (APTT, PT and fibrinogen), combined with a clotting FXIII assay as first‐line investigation. Subsequent assays of coagulation factors should be performed in the case of abnormal values, in second‐line investigation.


  • Quality of life of siblings of adolescents with severe haemophilia (FRATHEMO): An ancillary study to the TRANSHEMO project

    by Ngoc Anh Thu Nguyen, Pascal Auquier, Any Beltran Anzola, Annie Harroche, Yoann Huguenin, Audrey Hochart, Sandrine Meunier, Birgit Frotscher, Philippe Nguyen, Pascale Schneider, et al.


  • Emicizumab and asparaginase, A first experience to share

    by Laurie Goubeau, Cécile Bally, Delphine Borgel, Fanny Alby‐Laurent, Arnaud Petit, Laurent Frenzel, Dominique Lasne, Annie Harroche

  • The effects of time and temperature on the in vitro stability of emicizumab in blood samples: Implications for laboratory and clinical practices

    by Nûn K. Bentounes, Dominique Lasne, Capucine Habay, Cécile Bally, Laurent Frenzel, Annie Harroche, Delphine Borgel, Claire Auditeau


  • Interferences by factor VIII and lupus anticoagulant in the modified one‐stage assay for emicizumab

    by Capucine Habay, Claire Auditeau, Adeline Blandinières, Nûn K Bentounes, Cécile Lavenu‐Bombled, Annie Harroche, Cecile Bally, Laurent Frenzel, Delphine Borgel, Dominique Lasne


  • Determinants of adherence and consequences of the transition from adolescence to adulthood among young people with severe haemophilia (TRANSHEMO): A multicentric French national observational cross‐sectional study based on the FranceCoag registry

    by Ngoc Anh Thu Nguyen, Pascal Auquier, Any Beltran Anzola, Annie Harroche, Sabine Castet, Yoann Huguenin, Sandrine Meunier, Yohann Repesse, Roseline D'OIron, Antoine Rauch, et al.

    Introduction: It is necessary to gain insights into adherence to healthcare in people with severe haemophilia (PwSH), especially during the transition from paediatric to adult care, which is an important phase in lives of young people with childhood chronic disease. This adherence can be considered as a marker of successful transition.Objectives: The main objective of the quantitative phase of the TRANSHEMO project was to compare the adherence to healthcare between adolescents and young adults (YAs) with severe haemophilia. The secondary objective was to identify the determinants (facilitators and barriers) of this adherence and associations between these determinants.Methods: A multicentre, observational, cross‐sectional study was conducted in 2017–2019 on PwSH aged between 14 and 17 years (adolescents) or between 20 and 29 years (YAs), included in the FranceCoag registry and having completed the questionnaires. The adherence to healthcare (treatment regimens and clinical follow‐up) was compared between adolescents and YAs using the chi‐squared test. The determinants of this adherence were analysed by structural equation modelling.Results: There were 277 participants, 107 adolescents, and 170 YAs. The rate of adolescents adhering to healthcare was 82.2%, while the rate of YAs was 61.2% (p < .001). The barriers to the adherence to healthcare were being YA, having repeated at least one school grade and presenting mental health concerns.Conclusion: Adolescents had better adherence to healthcare than YAs. According to the determinants enlightened in this project, targeted supportive strategies and adapted therapeutic education programs can be developed for young PwSH to facilitate their adherence to healthcare.